Merck & Co. Inc. stock (US58933Y1055): Q1 results show revenue growth amid Keytruda strength

Merck & Co. Inc. released first-quarter financials showing revenue growth of 4.9% compared to the prior year, alongside a net margin of 13.59% and return on equity of 27.55%, as detailed in MarketBeat as of 05/13/2026. Separately, reports highlight an 8% stock jump after Q1 results beat expectations and upgraded 2026 guidance, with sales reaching significant levels driven by Keytruda.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co. Inc.: core business model

Merck & Co. Inc. operates as a leading global healthcare company focused on discovering, developing, and providing innovative products in human health pharmaceuticals and vaccines, as well as animal health. The company's portfolio centers on oncology, vaccines, and hospital acute care, with Keytruda as its blockbuster immunotherapy drug generating substantial revenue. This model emphasizes R&D investment, strategic acquisitions, and global commercialization to address unmet medical needs.

Main revenue and product drivers for Merck & Co. Inc.

Keytruda remains the primary revenue driver, contributing the largest share of pharmaceutical sales due to its dominance in cancer immunotherapy. In recent quarters, vaccines like Gardasil for HPV prevention have shown robust growth, while the animal health segment provides diversified income. First-quarter revenue rose 4.9% year-over-year, reflecting resilience amid patent cliffs and competitive pressures, per MarketBeat as of 05/13/2026.

Industry trends and competitive position

The pharmaceutical sector faces patent expirations, biosimilar competition, and rising R&D costs, yet oncology and immunotherapy markets continue expanding. Merck & Co. Inc. holds a strong position with Keytruda's market leadership, bolstered by recent deals and outlook upgrades noted in Simply Wall St coverage.

Why Merck & Co. Inc. matters for US investors

Listed on the NYSE, Merck & Co. Inc. offers US investors exposure to a blue-chip pharma stock with significant domestic revenue from Keytruda and vaccines, intertwined with the US healthcare economy and Medicare dynamics.

Conclusion

Merck & Co. Inc. demonstrated solid Q1 performance with revenue growth and strong profitability metrics, alongside positive market reaction to guidance upgrades. Investors track Keytruda's trajectory and pipeline progress amid sector headwinds. The company's US-centric revenue and NYSE listing maintain its appeal for American portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.